cytosine/neoplasms

FIELD OF THE INVENTION This invention relates to the use of lamivudine (3TC), emtricitabine (FTC), and Elvucitabine (L-FD4C or LFD4C), prodrugs or conjugates comprising these agents alone or along with another active agent, especially an anticancer agent or prodrug in the treatment of tumors,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the fields of molecular biology, developmental biology, cancer biology and medical therapeutics. Specifically, the present invention relates to novel DNA cytosine methyltransferases. More specifically,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the fields of molecular biology, developmental biology, cancer biology and medical therapeutics. Specifically, the present invention relates to novel de novo DNA cytosine methyltransferases. More

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2015 is named 12636350303.txt and is 12,531 bytes in size. BACKGROUND OF THE INVENTION 1. Field of

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 14, 2013, is named 12636350.txt and is 12,531 bytes in size. BACKGROUND OF THE INVENTION 1. Field of the

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 21, 2010, is named 12636350.txt and is 12,489 bytes in size. BACKGROUND OF THE INVENTION 1. Field of the

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to design, synthesis and application of oligonucleotide analogues which are useful as therapeutics, diagnostics as well as research reagents. Oligonucleotide analogues are provided that incorporate an analogue of

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 26, 2016 named 12636350401.txt and is 12,531 bytes in size. BACKGROUND OF THE INVENTION Field of the

BACKGROUND OF THE INVENTION The present invention concerns a method for the detection of 5-methylcytosine in DNA. 5-Methylcytosine is the most frequent covalently modified base in the DNA of eukaryotic cells. It plays an important biological role, among other things, in the regulation of

FIELD OF THE INVENTION The present invention relates to the use of cytosine nucleoside analogs and isoflavones and more particularly relates to their use for inhibiting undesirable proliferation of cells. BACKGROUND OF THE INVENTION Chemotherapy constitutes one of the major therapeutic approaches

BACKGROUND OF THE INVENTION The present invention concerns a method for the detection of 5-methylcytosine in DNA. 5-Methylcytosine is the most frequent covalently modified base in the DNA of eukaryotic cells. It plays an important biological role, among other things, in the regulation of

FIELD OF THE INVENTION This invention is in the area of medicinal chemistry, and in particular is (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC) and its use to treat cancer in animals, including humans. BACKGROUND OF THE INVENTION A tumor is an unregulated,

FIELD OF THE INVENTION This invention is in the area of medicinal chemistry, and in particular is (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC) or its derivative, and its use to treat cancer in animals, including humans. BACKGROUND OF THE INVENTION A tumor

FIELD OF THE INVENTION This invention is in the area of medicinal chemistry, and in particular is (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC) or its derivative, and its use to treat cancer in animals, including humans. BACKGROUND OF THE INVENTION A tumor

BACKGROUND In 2001, over 1.2 million new cases of human cancer will be diagnosed and over 0.5 million people will die from cancer (American Cancer Society estimate). Despite this, more people than ever are living with and surviving cancer. In 1997, for example, approximately 8.9 million living